Full Breakdown
TrumpRx “Generous” Pilot: A Year After Its Launch
By Drooid · · How we work
Core Event
In September 2025 the White House announced a voluntary pilot, dubbed the “Generous” model, in which drug manufacturers would offer Medicaid the most-favored-nation (MFN) price for selected medicines. The initiative, promoted as “TrumpRx,” was presented as the first of a series of agreements intended to bring U.S. prescription-drug costs down to levels paid by other wealthy nations. At the time, the administration said 26 pharmaceutical companies had signed deals, though the contracts have not been released.
Program Design and State Participation
The pilot relies on voluntary participation by both drug makers and individual states. Companies must submit a list of “eligible covered outpatient drugs” that will be offered at MFN rates, but the specific products remain undisclosed. The Centers for Medicare & Medicaid Services declined to reveal how many drugs each firm will discount. States must opt-in by a deadline that was originally set for spring-summer 2025 and later pushed back to September 10, 2026. Massachusetts announced it would join; California said it would apply while seeking more details. Opt-in requires states to abandon existing Medicaid coverage criteria and accept a standardized pricing system, raising concerns about budgetary exposure.
Medicaid Spending and Drug-Pricing Context
Medicaid covers roughly 66 million Americans. According to the Kaiser Family Foundation, net Medicaid spending on prescription drugs rose 46 % from 2019 to 2024, reaching $46 billion in 2024.
Official Statements & Responses
He framed the Pfizer agreement and subsequent company commitments as a major victory for low-income and disabled Americans on Medicaid. Federal officials have emphasized that the program is a pilot and that participation remains voluntary, but they have not disclosed the terms of the MFN discounts.
